Formulation, characterization and evaluation of gelatin-syringic acid/ zinc oxide nanocomposite for its effective anticancer, antioxidant and anti-inflammatory activities

Background: Hepatocellular carcinoma (HCC) is the most typical form of liver cancer. Apart from modern therapies, various natural chemical constituents have been tested for the treatment of HCC. However, the usage of the latter has declined due to their low bioavailability and stability.Objectives: Considering the above drawback's, in this study, we describe a gelatin-syringic acid/ zinc oxide (ZnO) nanocomposite for liver cancer treatment, which showed antioxidant, anti-inflammatory and anticancer activities.Methods: The hydrothermal method was used to synthesize ZnO nanoparticle and it was encapsulated with gelatin-syringic acid by coacervation technique. The nanocomposites were characterized by UV spec, FTIR, SEM, XRD, EDX, and DLS. The drug release profile of nanocomposite was studied by dialysis bag method, which exhibits a sustained drug release. Results: The antioxidant ability of nano-composite was studied by performing an ABTS and DPPH assay and the IC50 was recorded as 76.5 and 47.63 lg/mL, respectively. The anti-inflammatory potential was studied by assessing the ability of nanocomposite on denaturation of protein and the results exhibited a dose-dependent inhibition. The acute toxicity of nanocomposite tested on zebrafish liver and heart showed that it is non-toxic. Moreover, the nanocomposite inhibits the Hep G2 cell viability with an increasing concentration and it increases oxidative stress caused by the mitochondrial damage, which leads to cell death. Conclusion: Based on the findings of the present study, gelatin-syringic acid/ZnO nanocomposite has been shown to possess antioxidant, and anti-inflammatory properties, and thus can be used against HCC. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Automated summary

A gelatin-syringic acid/ZnO nanocomposite with antioxidant, anti-inflammatory, and anticancer activities was synthesized and characterized. The nanocomposite exhibited sustained drug release, high antioxidant ability, dose-dependent inhibition of protein denaturation, and non-toxicity in zebrafish. It also inhibited Hep G2 cell viability and increased oxidative stress caused by mitochondrial damage, leading to cell death. Overall, this study suggests that the gelatin-syringic acid/ZnO nanocomposite has potential for the treatment of hepatocellular carcinoma.